Evidence & Insights
The Evidence Behind the Problem.The Thinking & Early Evidence Behind the Solution.
For decades, researchers, patient organizations, and public institutions have documented the human, clinical, and economic burden of delayed rare disease diagnosis. Their work established the urgency of the problem. RDDT's clinical evidence, research, and Executive Perspectives explore a new approach to addressing it.
Explore the independent research that informed our mission, the evidence emerging from our work, and the ideas shaping the next chapter in rare disease medicine.
RDDT provides U.S. healthcare organizations with Rare Disease Patient Analytic Services, which combine compliant patient-first funding, proprietary analytics, independent clinical review, and patient-consented, physician-directed evaluation to create new, sustainable revenue for healthcare organizations while advancing earlier recognition and diagnosis of previously unsuspected rare disease patients for whom potentially life-saving FDA-approved therapies already exist, within their existing healthcare systems.
Foundational Research & Independent Reports
Independent research documenting the scale of rare disease, the diagnostic odyssey, the consequences of delayed recognition, and the burden on patients, families, and healthcare organizations.
Scientific Presentations
Peer-reviewed presentations and conference abstracts from RDDT's clinical and scientific team, covering methodology, early findings, and the analytical frameworks underlying our approach.
Clinical Evidence
Emerging clinical data from RDDT's operating programs — including performance metrics, patient identification rates, and outcomes from independent clinical evaluation.
Executive Perspectives
Thought leadership from RDDT's leadership team on the economics of rare disease diagnosis, the role of neutral intermediaries, and the future of clinically governed patient visibility.
Browse the Evidence Library
Access RDDT's curated collection of research, clinical presentations, and executive perspectives in our interactive digital bookshelf.
Explore by audience
Who does this evidence serve?
Healthcare Organizations
Evidence for health systems, hospitals, and data partners
See how RDDT's compliant architecture creates a new service line opportunity for healthcare organizations.
Learn more →BioPharma Manufacturers
Evidence for rare disease search sponsors
Understand the clinical and economic model that makes sponsor-funded, independently governed rare disease clinical visibility possible.
Learn more →Ready to Learn More?
The Evidence Is There. So Is the Path Forward.
RDDT's clinical model is built on decades of independent research and a growing body of real-world evidence. If you're ready to explore what this means for your organization, we'd welcome the conversation.
Contact Us"The patients are there. The therapies are there. What has been missing is the pathway to connect them."
Henri A. Termeer — Founding Inspiration, Rare Disease Data Trust